AK3280

Phase 3Small molecule

SShanghai Ark Biopharmaceutical Co., Ltd.

AK3280 is one of 3 small molecule programs targeting Idiopathic Pulmonary Fibrosis (IPF). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Idiopathic Pulmonary Fibrosis (IPF)Not yet recruiting

Idiopathic Pulmonary Fibrosis (IPF)Phase 3

Not yet recruiting

Competition

Competitive Landscape

6 competitors in Idiopathic Pulmonary Fibrosis (IPF)

#DrugCompanyPhaseTrials

Deupirfenidone

PPureTech

Phase 3

1 2

AK3280

SShanghai Ark Biopharmaceutical Co., Ltd.

Phase 3

1 3

LTI-03

RRein Therapeutics

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 3Not yet recruiting

Idiopathic Pulmonary Fibrosis (IPF)

NCT07719023

Clinical

Trials by Indication[1]

Function1 trial

A Study to Assess the Effect of AK3280 on Renal Function in Healthy Subjects

Completed·SShanghai Ark Biopharmaceutical Co., Ltd.·Phase 1·NCT03990688·48 enrolled

Idiopathic Pulmonary Fibrosis1 trial

A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis

Unknown status·SShanghai Ark Biopharmaceutical Co., Ltd.·Phase 2·NCT05424887·105 enrolled

Idiopathic Pulmonary Fibrosis (IPF)1 trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled and Open-Label Active-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Not yet recruiting·SShanghai Ark Biopharmaceutical Co., Ltd.·Phase 3·NCT07719023·263 enrolled

Hypertrophic Scar1 trial

A Randomized, Double-blind, Placebo Self-controlled Phase I/II Clinical Study to Evaluate the Safety, Tolerability and Preventive Efficacy of AK3280 Cream After Cicatrectomy in Patients With Hypertrophic Scar in China.

Completed·SShanghai Ark Biopharmaceutical Co., Ltd.·Preclinical·NCT05434897·30 enrolled

Unspecified1 trial

A Study of AK3280 in Chinese Healthy Volunteers

Completed·SShanghai Ark Biopharmaceutical Co., Ltd.·Phase 1·NCT04926116·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for AK3280. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AK3280 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AK3280. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Ark Biopharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SShanghai Ark Biopharmaceutical Co., Ltd.

AK3280

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Function1 trial

Idiopathic Pulmonary Fibrosis1 trial

Idiopathic Pulmonary Fibrosis (IPF)1 trial

Hypertrophic Scar1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News